GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Net-Net Working Capital

HighTide Therapeutics (HKSE:02511) Net-Net Working Capital : HK$1.37 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

HighTide Therapeutics's Net-Net Working Capital for the quarter that ended in Dec. 2023 was HK$1.37.

The industry rank for HighTide Therapeutics's Net-Net Working Capital or its related term are showing as below:

HKSE:02511's Price-to-Net-Net-Working-Capital is ranked better than
58.32% of 926 companies
in the Biotechnology industry
Industry Median: 4.19 vs HKSE:02511: 3.32

HighTide Therapeutics Net-Net Working Capital Historical Data

The historical data trend for HighTide Therapeutics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Net-Net Working Capital Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net-Net Working Capital
-0.68 -1.05 1.37

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Net-Net Working Capital -0.68 - -1.05 -2.24 1.37

Competitive Comparison of HighTide Therapeutics's Net-Net Working Capital

For the Biotechnology subindustry, HighTide Therapeutics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Price-to-Net-Net-Working-Capital falls into.


HighTide Therapeutics Net-Net Working Capital Calculation

HighTide Therapeutics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(804.694+0.75 * 0+0.5 * 0-100.914
-0-0)/514.771
=1.37

HighTide Therapeutics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(804.694+0.75 * 0+0.5 * 0-100.914
-0-0)/514.771
=1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

HighTide Therapeutics  (HKSE:02511) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

HighTide Therapeutics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Net-Net Working Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
Website
https://www.hightidetx.com
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Executives
Ma Lixiong 2101 Beneficial owner
Liu Liping 2101 Beneficial owner
Li Li 2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao 2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc. 2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p 2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited 2101 Beneficial owner
Hepalink (hong Kong) Limited 2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited 2101 Beneficial owner
Lai Hoi Man 2201 Interest of corporation controlled by you
Hongtu Capital Limited 2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines